Nuclear factor erythroid 2-like 2 (Nrf2) expression in end-stage liver disease

Environmental Toxicology and Pharmacology

Volumn 34, Issue 1, 2012, Pages 87-95

  Kurzawski, Mateusz ^a   Dziedziejko, Violetta ^a   Urasińska, Elzbieta ^a   Post, Mariola ^b   Wójcicki, Maciej ^b   Mietkiewski, Janusz ^b   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Marie Curie Hospital   (Poland)

Author keywords

End stage liver disease; KEAP1; Liver cirrhosis; Nrf2

Indexed keywords

CYTOKINE; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GLUTAMATE CYSTEINE LIGASE GENE; GLUTATHIONE S TRANSFERASE A1 GENE; HEME OXIDASE 1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KEAP1 GENE; LIVER FAILURE; LIVER TUMOR; MALE; METASTASIS POTENTIAL; NAD(P)H DEHYDROGENASE [QUINONE] 1 GENE; NFE2L2 GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE SECTION;

ADULT; CYTOKINES; FEMALE; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE-1; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER DISEASES; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; RNA, MESSENGER;

EID: 84858989085     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2012.03.001     Document Type: Article

References (23)

1. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
2. Choi H.K., Pokharel Y.R., Lim S.C., Han H.K., Ryu C.S., Kim S.K., Kwak M.K., Kang K.W. Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol. Appl. Pharmacol. 2009, 240:377-384.
3. Ellis E.L., Mann D.A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 2012, 10.1016/j.jhep.2011.09.024.
4. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000, 275:2247-2250.
5. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
6. Hammel P., Couvelard A., O'Toole D., Ratouis A., Sauvanet A., Fléjou J.F., Degott C., Belghiti J., Bernades P., Valla D., Ruszniewski P., Lévy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med. 2001, 344:418-423.
7. Kawata K., Kobayashi Y., Souda K., Kawamura K., Sumiyoshi S., Takahashi Y., Noritake H., Watanabe S., Suehiro T., Nakamura H. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patientswith primary biliary cirrhosis. Antioxid. Redox Signal. 2010, 13:259-268.
8. Klaassen C.D., Reisman S.A. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol. 2010, 244:57-65.
9. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., Igarashi K., Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004, 24:7130-7139.
10. Kwak M.K., Itoh K., Yamamoto M., Kensler T.W. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell Biol. 2002, 22:2883-2892.
11. Lamlé J., Marhenke S., Borlak J., von Wasielewski R., Eriksson C.J., Geffers R., Manns M.P., Yamamoto M., Vogel A. Nuclear factor-erythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008, 134:1159-1168.
12. Li W., Khor T.O., Xu C., Shen G., Jeong W.S., Yu S., Kong A.N. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 2008, 76:1485-1489.
13. Miao W., Hu L., Scrivens P.J., Batist G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem. 2005, 280:20340-20348.
14. Morito N., Yoh K., Itoh K., Hirayama A., Koyama A., Yamamoto M., Takahashi S. Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 2003, 22:9275-9281.
15. Okawa H., Motohashi H., Kobayashi A., Aburatani H., Kensler T.W., Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 2006, 339:79-88.
16. Osburn W.O., Yates M.S., Dolan P.D., Chen S., Liby K.T., Sporn M.B., Taguchi K., Yamamoto M., Kensler T.W. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol. Sci. 2008, 104:218-227.
17. Reichard J.F., Motz G.T., Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007, 35:7074-7086.
18. Svegliati-Baroni G., Saccomanno S., van Goor H., Jansen P., Benedetti A., Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001, 21:1-12.
19. Thimmulappa R.K., Lee H., Rangasamy T., Reddy S.P., Yamamoto M., Kensler T.W., Biswal S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 2006, 116:984-995.
20. Wang L., Groves M.J., Hepburn M.D., Bowen D.T. Glutathione-S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. Haematologica 2000, 85:573-579.
21. Xu W., Hellerbrand C., Köhler U.A., Bugnon P., Kan Y.W., Werner S., Beyer T.A. The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab. Invest. 2008, 88:1068-1078.
22. Yang H., Ramani K., Xia M., Ko K.S., Li T.W., Oh P., Li J., Lu S.C. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 2009, 49:1982-1991.
23. Zhu M., Fahl W.E. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem. Biophys. Res. Commun. 2001, 289:212-219.